Cargando…
Trastuzumab-Induced Interstitial Pneumonitis
Trastuzumab is a recombinant immunoglobulin G1 monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2) cancers. Trastuzumab-induced interstitial pneumonitis is a rare adverse effect reported in a few patients. Interstitial pneumonitis presents as symptoms of dyspnea, hypoxi...
Autores principales: | Errisuriz, Kimberly, Bazan, Daniela Z, Verduzco Jr., Rene, Guedez, Rosa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436675/ https://www.ncbi.nlm.nih.gov/pubmed/37602136 http://dx.doi.org/10.7759/cureus.42116 |
Ejemplares similares
-
Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast Cancer
por: Abulkhair, Omalkhair, et al.
Publicado: (2011) -
Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review
por: Costa, Ricardo, et al.
Publicado: (2017) -
Infliximab-Induced Interstitial Pneumonitis: A Case Report
por: Makkawy, Eyad A, et al.
Publicado: (2023) -
Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
por: Dumoulin, Daphne W., et al.
Publicado: (2020) -
Bucillamine‐induced interstitial pneumonitis
por: Nakamoto, Keitaro, et al.
Publicado: (2018)